Opinion
Video
Author(s):
Bita Fakhri, MD, MPH, shares her general approach to managing common cardiovascular adverse events associated with BTK inhibitors in patients with chronic lymphocytic leukemia.
Video content above is prompted by the following questions:
DESTINY-Breast12 Data Support T-DXd Use in HER2+ Breast Cancer, Irrespective of Brain Mets
Tivozanib Monotherapy Bests Lower-Dose Tivozanib Plus Nivolumab in Metastatic RCC
Frontline BMS-986012 Plus Nivolumab/Chemotherapy Shows Promise in ES-SCLC
Belzutifan Maintains PFS, ORR Benefits in Previously Treated Advanced Clear Cell RCC
2 Commerce Drive
Cranbury, NJ 08512